Safety and Efficacy of FSD201 for the Treatment of Chronic Pain Associated With Idiopathic MCAS (MCAD)
Trial details
- Registry ID
- NCT05652907
- Drugs studied
- FSD201
TrialRedline tracks 1 clinical trial sponsored by Quantum Biopharma: 1 Phase 2.
Company identity has not yet been verified
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| Safety and Efficacy of FSD201 for the Treatment of Chronic Pain Associated With Idiopathic MCAS (MCAD)NCT05652907 | FSD201 | Terminated | 2023-05-24Actual |
Names as written in the registry records.
NCT05652907 · Quantum Biopharma
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Targeted treatment effect of 30% decrease from baseline to Day 28 in the average daily pain intensity. After: Measure: Targeted Treatment Effect of 30% Decrease From Baseline to Day 28 in the Average Daily Pain Intensity.